Novel Regulators of Glucose Homeostasis in Aging
衰老过程中血糖稳态的新型调节剂
基本信息
- 批准号:8277249
- 负责人:
- 金额:$ 32.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-01 至 2015-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffectAgeAged, 80 and overAgingAlzheimer&aposs DiseaseApoptosisApoptoticAttenuatedBiologicalBiological FactorsBlood GlucoseBody CompositionBody fatBrainCardiovascular DiseasesCellsChronicClinicalComplexCytokine ReceptorsDataDependovirusDiabetes MellitusDiseaseDoseEnergy MetabolismEtiologyEuglycemic ClampingFatty acid glycerol estersFunctional disorderGlucose ClampGoalsHepaticHomeostasisHomologous GeneHumanHypothalamic structureIncidenceInfusion proceduresInsulinInsulin ResistanceInsulin-Like Growth Factor ILeadLinkLiverMammalsMediatingMediator of activation proteinMemory LossMetabolicMitochondriaModelingMolecularMusMuscleMyocardial IschemiaNeuraxisNeuronsNon-Insulin-Dependent Diabetes MellitusPathogenesisPathologyPatientsPeptidesPeripheralPhysiologicalPlasmaPlayPrevalencePreventionRattusResearchRiskRodentRodent ModelRoleScopolamineSerumSignal PathwaySkeletal MuscleStrokeSystemTechniquesTechnologyTestingTherapeuticTissuesVascular Smooth MuscleVisceralage relatedanalogbaseblood glucose regulationcarbohydrate metabolismdiabetes riskdiabeticglucose disposalglucose metabolismglucose productionhumaninimprovedinsulin sensitivityinsulin sensitizing drugsneuron lossneurotoxicitynoveloverexpressionpublic health relevancereceptorresponse
项目摘要
DESCRIPTION (provided by applicant): Biological changes associated with aging are a major risk for increased incidence of many age-related diseases including insulin resistance/type 2 diabetes mellitus, Alzheimer's disease (AD), stroke and ischemic heart disease. The focus of our research has been to identify biological factors that change with age and may be involved in the etiology or pathogenesis of age-related diseases. A novel mitochondrial peptide, Humanin (HN), has been recognized for its cyto-protective role due to its anti-apoptotic function in many tissues, especially AD related insults. In addition, HN is closely linked to the IGF system, which is recognized for its role in aging. In our preliminary data we show that that HN levels in tissues and secretions decrease with age. We also show that HN significantly improves overall insulin sensitivity both at the liver and skeletal muscle in young rats. Furthermore, molecular manipulations of HN create potent humanin analogs (that interact with IGF-1 system) that can reproduce the effects of native endogenous HN. Based on our preliminary data, we hypothesize that the decrease in HN levels increase risk of insulin resistance and diabetes in aging rodents, and this effect is mediated through the hypothalamus. Furthermore, we hypothesize that administration of HN to aging rodents will substantially alter the risk of diabetes. Using state of the art technology, we propose to evaluate the role of HN in the integral features that leads to the impaired glucose metabolism in aging: a) diminished ability of insulin to restrain the production of glucose from the liver (or hepatic glucose production) and/or to promote the disposal of glucose in peripheral tissues, in part by a central mechanism, and b) increase in fat especially visceral fat. HN represents a novel molecular link between impaired carbohydrate metabolism, diabetes and neuro-degeneration, and may provide not only mechanistic explanations but also potential therapeutic options in this common clinical constellation affecting millions of people.
PUBLIC HEALTH RELEVANCE: With age, there is an increase in the incidence of disease such as type 2 diabetes and Alzheimer's disease (AD). These two diseases are linked to each other in that insulin resistance contributes to the pathogenesis and progression of AD. Humanin (HN) is a novel peptide that has been shown to protect against AD. Our preliminary results suggest that HN, in addition to its role in AD also improves insulin action. Here, in this proposal we explore the role of HN in insulin resistance and metabolic decline in aging.
描述(由申请人提供):与衰老相关的生物变化是许多与年龄相关的疾病发病率增加的主要风险,包括胰岛素抵抗/2型糖尿病、阿尔茨海默氏病(AD)、中风和缺血性心脏病。我们研究的重点是确定随年龄变化的生物因素,这些因素可能与年龄相关疾病的病因或发病机制有关。护脑素 (HN) 是一种新型线粒体肽,因其在许多组织(尤其是 AD 相关损伤)中的抗凋亡功能而被认为具有细胞保护作用。此外,HN 与 IGF 系统密切相关,IGF 系统因其在衰老中的作用而受到认可。在我们的初步数据中,我们表明组织和分泌物中的 HN 水平随着年龄的增长而降低。我们还表明,HN 显着提高了年轻大鼠肝脏和骨骼肌的整体胰岛素敏感性。此外,HN 的分子操作产生了有效的护脑素类似物(与 IGF-1 系统相互作用),可以重现天然内源性 HN 的作用。根据我们的初步数据,我们假设 HN 水平的降低会增加老年啮齿动物胰岛素抵抗和糖尿病的风险,并且这种效应是通过下丘脑介导的。此外,我们假设对老年啮齿动物施用 HN 将大大改变患糖尿病的风险。使用最先进的技术,我们建议评估 HN 在导致衰老过程中葡萄糖代谢受损的整体特征中的作用:a) 胰岛素抑制肝脏产生葡萄糖(或肝葡萄糖产生)的能力减弱和/或部分地通过中枢机制促进外周组织中葡萄糖的处理,以及b)脂肪尤其是内脏脂肪的增加。 HN 代表了碳水化合物代谢受损、糖尿病和神经变性之间的一种新型分子联系,不仅可以提供机制解释,还可以为影响数百万人的这一常见临床群提供潜在的治疗选择。
公共卫生相关性:随着年龄的增长,2 型糖尿病和阿尔茨海默病 (AD) 等疾病的发病率会增加。这两种疾病相互关联,因为胰岛素抵抗导致 AD 的发病机制和进展。护脑素 (HN) 是一种新型肽,已被证明可以预防 AD。我们的初步结果表明,HN 除了在 AD 中发挥作用外,还可以改善胰岛素的作用。在这里,在本提案中,我们探讨了 HN 在胰岛素抵抗和衰老过程中代谢下降中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Radhika Hiren Muzumdar其他文献
Radhika Hiren Muzumdar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Radhika Hiren Muzumdar', 18)}}的其他基金
Novel Regulators of Glucose Homeostasis in Aging
衰老过程中血糖稳态的新型调节剂
- 批准号:
8068345 - 财政年份:2010
- 资助金额:
$ 32.51万 - 项目类别:
Novel Regulators of Glucose Homeostasis in Aging
衰老过程中血糖稳态的新型调节剂
- 批准号:
8114665 - 财政年份:2010
- 资助金额:
$ 32.51万 - 项目类别:
Novel Regulators of Glucose Homeostasis in Aging
衰老过程中血糖稳态的新型调节剂
- 批准号:
8459465 - 财政年份:2010
- 资助金额:
$ 32.51万 - 项目类别:
Novel Regulators of Glucose Homeostasis in Aging
衰老过程中血糖稳态的新型调节剂
- 批准号:
8817892 - 财政年份:2010
- 资助金额:
$ 32.51万 - 项目类别:
CNS/IGF-axis in modulation of body composition in aging
CNS/IGF 轴在衰老过程中调节身体成分
- 批准号:
7913491 - 财政年份:2009
- 资助金额:
$ 32.51万 - 项目类别:
CNS/IGF-axis in modulation of body composition in aging
CNS/IGF 轴在衰老过程中调节身体成分
- 批准号:
7896468 - 财政年份:2007
- 资助金额:
$ 32.51万 - 项目类别:
CNS/IGF-axis in modulation of body composition in aging
CNS/IGF 轴在衰老过程中调节身体成分
- 批准号:
8111754 - 财政年份:2007
- 资助金额:
$ 32.51万 - 项目类别:
CNS/IGF-axis in modulation of body composition in aging
CNS/IGF 轴在衰老过程中调节身体成分
- 批准号:
7467975 - 财政年份:2007
- 资助金额:
$ 32.51万 - 项目类别:
CNS/IGF-axis in modulation of body composition in aging
CNS/IGF 轴在衰老过程中调节身体成分
- 批准号:
7260075 - 财政年份:2007
- 资助金额:
$ 32.51万 - 项目类别:
CNS/IGF-axis in modulation of body composition in aging
CNS/IGF 轴在衰老过程中调节身体成分
- 批准号:
7671336 - 财政年份:2007
- 资助金额:
$ 32.51万 - 项目类别:
相似国自然基金
基于年龄和空间的非随机混合对性传播感染影响的建模与研究
- 批准号:12301629
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
- 批准号:82373667
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
母传抗体水平和疫苗初种年龄对儿童麻疹特异性抗体动态变化的影响
- 批准号:82304205
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
年龄结构和空间分布对艾滋病的影响:建模、分析与控制
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
随机噪声影响下具有年龄结构的布鲁氏菌病动力学行为与最优控制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
A rigorous test of dual process model predictions for problematic alcohol involvement
对有问题的酒精参与的双过程模型预测的严格测试
- 批准号:
10679252 - 财政年份:2023
- 资助金额:
$ 32.51万 - 项目类别:
The Role of Dopamine in Cognitive Resilience to Alzheimer's Disease Pathology in Healthy Older Adults
多巴胺在健康老年人阿尔茨海默氏病病理认知弹性中的作用
- 批准号:
10678125 - 财政年份:2023
- 资助金额:
$ 32.51万 - 项目类别:
Effects of Aging on Neuronal Lysosomal Damage Responses Driven by CMT2B-linked Rab7
衰老对 CMT2B 相关 Rab7 驱动的神经元溶酶体损伤反应的影响
- 批准号:
10678789 - 财政年份:2023
- 资助金额:
$ 32.51万 - 项目类别:
The Role of Outpatient Diuretic Therapy in Bronchopulmonary Dysplasia
门诊利尿疗法在支气管肺发育不良中的作用
- 批准号:
10663469 - 财政年份:2023
- 资助金额:
$ 32.51万 - 项目类别: